Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants

The Food and Drug Administration (FDA) has approved MAPK inhibitors as a treatment for melanoma patients carrying a mutation in codon V600 of the BRAF gene exclusively. However, BRAF mutations outside the V600 codon may occur in a small percentage of melanomas. Although these rare variants may cause...

Descripción completa

Detalles Bibliográficos
Autores principales: Scaini, Maria Chiara, Piccin, Luisa, Bassani, Davide, Scapinello, Antonio, Pellegrini, Stefania, Poggiana, Cristina, Catoni, Cristina, Tonello, Debora, Pigozzo, Jacopo, Dall’Olmo, Luigi, Rosato, Antonio, Moro, Stefano, Chiarion-Sileni, Vanna, Menin, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418914/
https://www.ncbi.nlm.nih.gov/pubmed/37569660
http://dx.doi.org/10.3390/ijms241512285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418914/
https://www.ncbi.nlm.nih.gov/pubmed/37569660
http://dx.doi.org/10.3390/ijms241512285

Ejemplares similares